FR2823207B1 - Complexes d'anilides a chaine polycarbonee et de cyclodestrines, leur preparation et leur application en tant que medicamment en particulier pour le traitement des dislipidemies - Google Patents

Complexes d'anilides a chaine polycarbonee et de cyclodestrines, leur preparation et leur application en tant que medicamment en particulier pour le traitement des dislipidemies

Info

Publication number
FR2823207B1
FR2823207B1 FR0104855A FR0104855A FR2823207B1 FR 2823207 B1 FR2823207 B1 FR 2823207B1 FR 0104855 A FR0104855 A FR 0104855A FR 0104855 A FR0104855 A FR 0104855A FR 2823207 B1 FR2823207 B1 FR 2823207B1
Authority
FR
France
Prior art keywords
cyclodestrins
dislipidemia
medicinally
anilides
complexes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR0104855A
Other languages
English (en)
Other versions
FR2823207A1 (fr
Inventor
Joel Bougaret
Elie Leverd
Marie Dominique Ibarra
Alexandre Gil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Priority to FR0104855A priority Critical patent/FR2823207B1/fr
Priority to EP02761926A priority patent/EP1377545A1/fr
Priority to US10/474,781 priority patent/US6864246B2/en
Priority to CA002444253A priority patent/CA2444253A1/fr
Priority to PCT/FR2002/001224 priority patent/WO2002083632A1/fr
Priority to JP2002581389A priority patent/JP2004531525A/ja
Publication of FR2823207A1 publication Critical patent/FR2823207A1/fr
Application granted granted Critical
Publication of FR2823207B1 publication Critical patent/FR2823207B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
FR0104855A 2001-04-10 2001-04-10 Complexes d'anilides a chaine polycarbonee et de cyclodestrines, leur preparation et leur application en tant que medicamment en particulier pour le traitement des dislipidemies Expired - Lifetime FR2823207B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR0104855A FR2823207B1 (fr) 2001-04-10 2001-04-10 Complexes d'anilides a chaine polycarbonee et de cyclodestrines, leur preparation et leur application en tant que medicamment en particulier pour le traitement des dislipidemies
EP02761926A EP1377545A1 (fr) 2001-04-10 2002-04-09 Complexes d'anilides et de cyclodextrines, leur preparation et leur application en tant que medicament en particulier pour le traitement des dislipidemies
US10/474,781 US6864246B2 (en) 2001-04-10 2002-04-09 Anilide and cyclodextrin complexes, their preparation and their use as medicine in particular for treating dyslipidemiae
CA002444253A CA2444253A1 (fr) 2001-04-10 2002-04-09 Complexes d'anilides et de cyclodextrines, leur preparation et leur application en tant que medicament en particulier pour le traitement des dislipidemies
PCT/FR2002/001224 WO2002083632A1 (fr) 2001-04-10 2002-04-09 Complexes d'anilides et de cyclodextrines, leur preparation et leur application en tant que medicament en particulier pour le traitement des dislipidemies
JP2002581389A JP2004531525A (ja) 2001-04-10 2002-04-09 アニリドとシクロデキストリンとの複合体、その製造および特に異常脂肪血症の治療のための医薬としてのその使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0104855A FR2823207B1 (fr) 2001-04-10 2001-04-10 Complexes d'anilides a chaine polycarbonee et de cyclodestrines, leur preparation et leur application en tant que medicamment en particulier pour le traitement des dislipidemies

Publications (2)

Publication Number Publication Date
FR2823207A1 FR2823207A1 (fr) 2002-10-11
FR2823207B1 true FR2823207B1 (fr) 2004-12-03

Family

ID=8862147

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0104855A Expired - Lifetime FR2823207B1 (fr) 2001-04-10 2001-04-10 Complexes d'anilides a chaine polycarbonee et de cyclodestrines, leur preparation et leur application en tant que medicamment en particulier pour le traitement des dislipidemies

Country Status (6)

Country Link
US (1) US6864246B2 (fr)
EP (1) EP1377545A1 (fr)
JP (1) JP2004531525A (fr)
CA (1) CA2444253A1 (fr)
FR (1) FR2823207B1 (fr)
WO (1) WO2002083632A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2854079B1 (fr) * 2003-04-25 2007-11-30 Pf Medicament Procede de preparation de complexes moleculaires
US7781572B2 (en) * 2005-10-05 2010-08-24 Nse Products, Inc. Nanosized carotenoid cyclodextrin complexes
WO2014145443A2 (fr) * 2013-03-15 2014-09-18 The Board Of Regents Of The University Of Texas System Liquides riches en gaz noble et leurs procédés de préparation et d'utilisation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4407795A (en) * 1981-07-16 1983-10-04 American Cyanamid Company Inclusion compound of p-hexadecylamino benzoic acid in cyclodextrin and method of use
FR2741619B1 (fr) * 1995-11-28 1998-02-13 Pf Medicament Nouveaux derives de 2,3,5-trimethyl-4-hydroxy-anilides, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
EP1377545A1 (fr) 2004-01-07
FR2823207A1 (fr) 2002-10-11
CA2444253A1 (fr) 2002-10-24
JP2004531525A (ja) 2004-10-14
US6864246B2 (en) 2005-03-08
US20040127462A1 (en) 2004-07-01
WO2002083632A1 (fr) 2002-10-24

Similar Documents

Publication Publication Date Title
FR17C1042I2 (fr) Nouvelles compositions immunogenes pour la prevention et le traitement de la meningite a meningocoques
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
DZ2752A1 (fr) Composés et compositions pharmaceutiques pour le traitement du paludisme.
DZ3165A1 (fr) Composition alimentaire ou pharmaceutique utiliseepour prevenir ou traiter l'hyperoxalurie.
PT1313489E (pt) Composicoes farmaceuticas para o tratamento de mucosite, estomatite e sindroma de behcet
DE69929996D1 (de) Pharmazeutisches mittel zur behandlung von diabetes
FR2775596B1 (fr) Nouvelles compositions pharmaceutiques
BR0214263B1 (pt) processos para a preparaÇço de uma composiÇço para o tratamento dos cabelos.
MA26536A1 (fr) Association de compositions pharmaceutiques d'atorvastatine et d'agents antihypertensifs, et procede pour leur preparation.
PT914118E (pt) 3,5-difenil-1,2,4-triazoles substituidos e sua utilizacao como quelantes farmaceuticos de metais
ATE277615T1 (de) Therapeutische zusammensetzungen, enthaltend amlopidin und atorvastatin
EE05475B1 (et) Superantigeeni sisaldav konjugaat, konjugaadi kasutamine ja konjugaati sisaldav farmatseutiline kompositsioon
DE10082139T1 (de) Zusammensetzung zur Behandlung von Reibungspaaren
BR9814923A (pt) Método para tratamento de doença de alzheimer
CH1143977H1 (fr) 2-Oxy-benzoxazine-4-ones destinees au traitement de l'obesite
EE200100179A (et) Farmatseutilised agendid Parkinsoni tõve, ADHD jamikroadenoomide raviks
MA27076A1 (fr) Regime de dosage et composition pharmaceutique pour contraception d'urgence
DZ3014A1 (fr) Médicaments pour le traitement de l'hypertension.
YU13301A (sh) Muskarinski agonisti i antagonisti
PT1355906E (pt) Derivados de 2h-1-benzopirano processos para a sua preparacao e as suas composicoes farmaceuticas
PT1107793E (pt) Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados
FR2823207B1 (fr) Complexes d'anilides a chaine polycarbonee et de cyclodestrines, leur preparation et leur application en tant que medicamment en particulier pour le traitement des dislipidemies
EP1443932A4 (fr) Compositions pharmaceutiques contenant des 3,4-propinoperhydropurines et utilisations de celles-ci pour bloquer la transmission neuronale
MA26117A1 (fr) Nouveau compose pour le traitement de l'impuissance
ID25478A (id) Agonis 5-ht1f